Legend Biotech (LEGN) vs Telix Pharmaceuticals (TLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Telix Pharmaceuticals (TLX) has outperformed Legend Biotech (LEGN) over the past year, gaining 11.8% versus a loss of 39.1%. Telix Pharmaceuticals is the larger company by market cap ($3.74 billion vs $3.61 billion), about 1.0 times the size, while Legend Biotech is growing revenue faster (+64.0% vs +55.6%). Telix Pharmaceuticals converts more of its revenue into profit, with a net margin of -0.9% versus -28.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LEGN | TLX |
|---|---|---|
| Share price | $18.58 | $11.02 |
| Market cap | $3.61B | $3.74B |
| 1-day change | -2.82% | -0.91% |
| YTD return | -12.05% | +48.46% |
| 1-year return | -39.13% | +11.76% |
| 5-year return | -63.17% | — |
| P/E ratio (TTM) | — | 110.19 |
| Forward P/E | 17.70 | — |
| EPS (TTM) | $-0.52 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.03B | $803.79M |
| Revenue growth (YoY) | +64.04% | +55.61% |
| Net income (latest FY) | $-296.80M | $-7.13M |
| Gross margin | 61.41% | 53.05% |
| Operating margin | -13.27% | 3.70% |
| Net margin | -28.85% | -0.89% |
| 52-week high | $37.50 | $13.11 |
| 52-week low | $16.24 | $6.28 |
| Distance from 52-week high | -50.45% | -15.95% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +150.27% | +85.32% |
| Average volume | 2.36M | 258.23K |
| Shares outstanding | 194.49M | 339.78M |
| Employees | 3,200 | 1,120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLX has outperformed LEGN by 50.9 percentage points over the past year.
- Telix Pharmaceuticals is more profitable, keeping -0.9 cents of every revenue dollar as net income versus -28.8 cents for Legend Biotech.
- Legend Biotech grew revenue faster in its latest fiscal year (+64.04% vs +55.61%).
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,200 employees
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
LEGN vs TLX FAQ
Which is bigger, Legend Biotech or Telix Pharmaceuticals?
Telix Pharmaceuticals (TLX) is larger, with a market capitalization of $3.74B compared with $3.61B for Legend Biotech (LEGN).
Which stock has performed better over the past year, LEGN or TLX?
TLX returned +11.76% over the past 12 months, compared with -39.13% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Are Legend Biotech and Telix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.